DelveInsight’s, “Niemann Pick C Disease Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Niemann-Pick Type Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight

Key Takeaways from the Niemann-Pick Type Pipeline Report

• On June 04, 2026, Azafaros A.G initiated a phase 3 study is to demonstrate superior efficacy on ataxic manifestations with oral nizubaglustat dosing compared with placebo when administered over 18 months in participants with late-infantile and juvenile forms of NPC disease
• DelveInsight’s Niemann-Pick Type pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Niemann-Pick Type treatment.
• The leading Niemann-Pick Type Companies such as Cyclo Therapeutics, Azafaros, IntraBio and others.
• Promising Niemann-Pick Type Pipeline Therapies such as arimoclomol, IB1001, Miglustat, Hydroxypropyl-beta-cyclodextrin, nizubaglustat, and others.

Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Niemann-Pick Type Clinical Trials and Studies

Niemann-Pick Disease Overview

Niemann-Pick disease (NPD) is a group of inherited metabolic disorders characterized by the abnormal accumulation of lipids in various tissues of the body. This accumulation leads to the progressive deterioration of cells and organs, including the liver, spleen, lungs, bone marrow, and brain. There are different types of Niemann-Pick disease, classified primarily into Types A, B, and C, each distinguished by genetic cause, clinical features, and progression. The disease is caused by mutations in genes responsible for lipid metabolism, particularly the SMPD1 gene (Types A and B) and NPC1 or NPC2 genes (Type C). These mutations disrupt normal lipid processing and trafficking, leading to lipid buildup in cells.

Niemann-Pick Type Emerging Drugs Profile

• Trappsol Cyclo: Cyclo Therapeutics

Trappsol Cyclo is a proprietary therapeutic formulation developed by Cyclo Therapeutics, Inc., primarily aimed at treating Niemann-Pick Disease Type C1 (NPC1). The drug is composed of 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD), which acts by facilitating the transport of excess cholesterol out of lysosomes. In NPC1, the defective NPC1 protein prevents effective cholesterol transport, leading to toxic buildup. Trappsol Cyclo mimics this protein’s function, helping to restore normal cholesterol homeostasis within cells. The drug is currently in a Phase III trial aimed at evaluating its long-term efficacy and safety in NPC patients. Previous Phase I and Phase II studies have shown promising results, indicating clinical benefits such as stabilization or slowing of disease progression.

• Nizubaglustat: Azafaros

Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including Niemann-Pick disease type C (NPC). The results of the Phase II RAINBOW study mark a pivotal moment in the development of nizubaglustat. The dual mode of action sets nizubaglustat apart as a leap forward from other agents. The company plans to initiate a Phase III trial for the treatment of NPC by 2025.

The Niemann-Pick Type Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Niemann-Pick Type with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Niemann-Pick Type Treatment.
• Niemann-Pick Type Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Niemann-Pick Type Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Niemann-Pick Type market.

Get a detailed analysis of the latest innovations in the Niemann-Pick Type Pipeline @ Niemann-Pick Type Unmet Needs

Niemann-Pick Type Companies

Cyclo Therapeutics, Azafaros, IntraBio and others.

Niemann Pick C Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Niemann-Pick Type Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies @ Niemann-Pick Type Market Drivers and Barriers, and Future Perspectives

Scope of the Niemann-Pick Type Pipeline Report

• Coverage- Global
• Niemann-Pick Type Companies- Cyclo Therapeutics, Azafaros, IntraBio and others.
• Niemann-Pick Type Pipeline Therapies- arimoclomol, IB1001, Miglustat, Hydroxypropyl-beta-cyclodextrin, Nizubaglustat, miglustat and others.
• Niemann-Pick Type Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Niemann-Pick Type Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Pipeline Report @ Niemann-Pick Type Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Niemann-Pick Type Disease: Overview
4. Niemann-Pick Type Disease Pipeline Therapeutics
5. Niemann-Pick Type Disease Pipeline Therapeutic Assessment
6. Niemann Pick C Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Registration)
8. Trappsol Cyclo: Cyclo Therapeutics
9. Mid Stage Products (Phase II)
10. Nizubaglustat: Azafaros
11. Early Stage Products (Phase I/II)
12. Drug Name: Company Name
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Niemann-Pick Type Disease Key Companies
17. Niemann-Pick Type Disease Key Products
18. Niemann-Pick Type Disease- Unmet Needs
19. Niemann-Pick Type Disease- Market Drivers
20. Niemann-Pick Type Disease Market Barriers
21. Niemann-Pick Type Disease- Future Perspectives and Conclusion
22. Niemann-Pick Type Disease Analyst Views
23. Niemann-Pick Type Disease Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/niemann-pick-disease-pipeline-insight